Aca­dia de­clares ear­ly win on Nu­plazid de­men­tia study, stun­ning an­a­lysts and send­ing shares soar­ing

Aca­dia Phar­ma­ceu­ti­cals — mak­er of the con­tro­ver­sial psy­chosis drug Nu­plazid — is halt­ing a late-stage tri­al in pa­tients with de­men­tia af­ter the com­pa­ny re­port­ed it had ob­tained enough pos­i­tive da­ta at an in­ter­im read­out to make its pitch to the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER